MilWealth Group’s DexCom DXCM Stock Holding History

MilWealth Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4	Closed	-$537	–	105
2021 Q4	$537	Hold	4	–	–	﹤0.01%	156
2021 Q3	$547	Buy	+4	New	+$504	﹤0.01%	170

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

MilWealth Group's DXCM Position: Q1 2022 in Review

MilWealth Group sold out of DexCom (DXCM) in Q1 2022, closing a stake of 4 shares — an estimated $537 sold.

MilWealth Group first reported a position in DXCM in Q3 2021 and held it in 2 quarters. The position peaked at $547 in Q3 2021. 861 funds tracked by Wall St. Rank hold DXCM as of Q1 2022.

MilWealth Group reported no remaining DexCom position as of Q1 2022 after selling out during the quarter.
MilWealth Group sold 4 DexCom shares in Q1 2022, an estimated $537.
MilWealth Group first reported a position in DexCom in Q3 2021 and held it in 2 quarters.
MilWealth Group's DexCom position peaked at $547 in Q3 2021.
861 funds tracked by Wall St. Rank held DexCom as of Q1 2022.

Based on MilWealth Group's 13F filing for Q1 2022, filed 9 May 2023.